• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Daiichi Sankyo Company, Ltd (4568) - Financial and Strategic SWOT Analysis Review Product Image

Daiichi Sankyo Company, Ltd (4568) - Financial and Strategic SWOT Analysis Review

  • Published: April 2011
  • 46 pages
  • GlobalData

FEATURED COMPANIES

  • Abviva, Inc.
  • Astellas Pharma Inc.
  • Merck & Co., Inc.
  • Shionogi & Co., Ltd.
  • MORE

Daiichi Sankyo Company, Ltd (4568) - Financial and Strategic SWOT Analysis Review

Summary

Daiichi Sankyo Company, Ltd (Daiichi Sankyo) is a holding company engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, OTC drugs, and quasidrugs. The company's business operations are classified into two segments, namely, Pharmaceuticals and Others. The company’s products are marketed directly by its Japanese and global group companies. Daiichi Sankyo's sells its products in 33 locations with about 2,300 overseas medical representatives. The company’s operations are spread across North America, South America, Europe and Asia Pacific. The company is headquartered in Tokyo, Japan.

Daiichi Sankyo Company, Ltd Key Recent Developments…

Jan 31, 2011: Daiichi Sankyo Reports Net Income For 9M Ended Fiscal 2010
Sep 30, 2010: Daiichi Sankyo Espha Begins Operations In Japan To Sell Generics And Long-Listed, Off-Patent Pharmaceuticals
Sep 29, 2010: Daiichi Sankyo Announces Launch Date In Japan For Inavir Influenza Antiviral Inhalant
Sep 29, 2010: KINAXO And Daiichi READ MORE >



List of Tables
List of Figures
Section 1 - About the Company
Daiichi Sankyo Company, Ltd - Key Facts
Daiichi Sankyo Company, Ltd - Key Employees
Daiichi Sankyo Company, Ltd - Key Employee Biographies
Daiichi Sankyo Company, Ltd - Key Operational Employees
Daiichi Sankyo Company, Ltd - Major Products and Services
Daiichi Sankyo Company, Ltd - Pharmaceutical Pipeline Products Data
Daiichi Sankyo Company, Ltd, Pipeline Products by Therapy Area
Daiichi Sankyo Company, Ltd, Pipeline Products by Development Phase
Daiichi Sankyo Company, Ltd - History
Daiichi Sankyo Company, Ltd - Company Statement
Daiichi Sankyo Company, Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Daiichi Sankyo Company, Ltd - Key Manufacturing Facilities
Joint Venture
Section 2 – Company Analysis
Daiichi Sankyo Company, Ltd - Business Description
Daiichi Sankyo Company, Ltd - SWOT Analysis
SWOT Analysis - Overview
Daiichi Sankyo Company, Ltd - Strengths
Strength - Sound Financial Performance
Strength - Select Acquisitions
Strength - Widespread Global Operations
Strength - Sturdy Research and Development Activities
Daiichi Sankyo Company, Ltd - Weaknesses
Weakness - Product Discontinuations
Weakness - Fallout of the US Import Ban on Ranbaxy Drugs
Daiichi Sankyo Company, Ltd - Opportunities
Opportunity - Changing Demographics
Opportunity - Growth in Emerging Markets
Opportunity - Implementation of Business Strategies
Opportunity - Rich Product Pipeline
Daiichi Sankyo Company, Ltd - Threats
Threat - Presence of Counterfeit Drugs
Threat - Changing Government Regulations
Threat - Increasing Foreign Competition
Threat - Uncertain R&D Outcomes
Daiichi Sankyo Company, Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Daiichi Sankyo Company, Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Daiichi Sankyo Company, Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Daiichi Sankyo Company, Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 31, 2011: Daiichi Sankyo Reports Net Income For 9M Ended Fiscal 2010
Sep 30, 2010: Daiichi Sankyo Espha Begins Operations In Japan To Sell Generics And Long-Listed, Off-Patent Pharmaceuticals
Sep 29, 2010: Daiichi Sankyo Announces Launch Date In Japan For Inavir Influenza Antiviral Inhalant
Sep 29, 2010: KINAXO And Daiichi Sankyo Sign Collaboration Agreement
Aug 04, 2010: Daiichi Sankyo Settles Patent Litigation For Evoxac
Jul 21, 2010: Daiichi Sankyo To Leverage Ranbaxy’s Network To Market Tavanic In Romania And South Africa
Jul 02, 2010: Daiichi Sankyo And Ranbaxy To Integrate New Drug Research And Development System
May 25, 2010: HCRI Expands DAPT Study Into Europe
May 12, 2010: Daiichi Sankyo Announces New Executive Candidates
Apr 19, 2010: Daiichi Sankyo Introduces Rezaltas Combination Tablets In Japan
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Abviva, Inc.
Shionogi & Co., Ltd.
Astellas Pharma Inc.
Kyowa Hakko Kirin Co., Ltd.
CardioVascular BioTherapeutics, Inc.
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS